Bleeding Risk Reduction in Relation to Predicted Factor IX Levels in Hemophilia B Patients Receiving Idelvion (rIX-FP)

被引：0
|
作者：
Roberts, John [1 ]
Fosser, Cecilia [2 ]
Tortorici, Michael [1 ]
Veldman, Alex [3 ]
Jacobs, Iris C. [4 ]
Sidhu, Jagdev [5 ]
机构：
[1] CSL Behring, King Of Prussia, PA USA
[2] Cytel, Cambridge, MA USA
[3] CSL Behring, Marburg, Germany
[4] CSL Behring, CRD, King Of Prussia, PA USA
[5] CSL, Parkville, Vic, Australia
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1411.1411
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1411
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Identifying Efficacious Thresholds for Bleeding Risk Reduction in Relation to Factor IX (FIX) Levels in Hemophilia B Patients Receiving IDELVION
    Fosser, C.
    Roberts, J.
    Tortorici, M.
    Jacobs, I.
    Sidhu, J.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S15 - S15
  • [2] SAFETY AND EFFICACY OF RECOMBINANT FACTOR IX FUSION PROTEIN (RIX-FP) IN PUPS WITH HEMOPHILIA B
    Lemons, Richard
    Wang, Michael
    Curtin, Julie
    Lepatan, Lynda Mae
    Male, Christoph
    Peyvandi, Flora
    Von Depka, Mario
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S174 - S175
  • [3] Resolution of Target Joints In Patients With Hemophilia B Receiving Once Weekly Prophylaxis With RIX-FP
    Hanabusa, H.
    Negrier, C.
    Juergen-Laws, H.
    Lissitchkov, T.
    Castaman, G.
    Tagliaferri, A.
    Fukutake, K.
    Lopez-Fernandez, M. F.
    Veldman, A.
    Santagostino, E.
    HAEMOPHILIA, 2017, 23 : 52 - 52
  • [4] Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤ 2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program
    Laws, Hans-Juergen
    Fukutake, Katsuyuki
    Lopez-Fernandez, Maria Fernanda
    Li, Yanyan
    Seifert, Wilfried
    Tagliaferri, Annarita
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (02) : 293 - 299
  • [5] Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
    Santagostino, Elena
    Negrier, Claude
    Klamroth, Robert
    Tiede, Andreas
    Pabinger-Fasching, Ingrid
    Voigt, Christine
    Jacobs, Iris
    Morfini, Massimo
    BLOOD, 2012, 120 (12) : 2405 - 2411
  • [6] Population pharmacokinetic model for a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
    Parasrampuria, R.
    Easton, R.
    Yao, Z.
    Bensen-Kennedy, D.
    Voigt, C.
    Jacobs, I
    Massimo, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 829 - 829
  • [7] Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP
    Davis, Joanna
    Yan, Songkai
    Matsushita, Tadashi
    Alberio, Lorenzo
    Bassett, Paul
    Santagostino, Elena
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 1014 - 1021
  • [8] Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
    Lemons, Richard
    Wang, Michael
    Curtin, Julie
    Lepatan, Lynda Mae
    Male, Christoph
    Peyvandi, Flora
    Prondzinski, Mario von Depka
    Wang, Rongrong
    McKeand, William
    Seifert, Wilfried
    Oldenburg, Johannes
    TH OPEN, 2024, 08 (01) : e155 - e163
  • [9] High compliance to prophylaxis regimens in adult and paediatric hemophilia B patients receiving RIX-FP in clinical studies
    Altisent, C.
    Kenet, G.
    Oldenburg, J.
    Chan, A.
    Boggio, L.
    Seifert, W.
    Santagostino, E.
    HAEMOPHILIA, 2018, 24 : 64 - 64
  • [10] Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B
    Gill, Joan C.
    Roberts, John
    Li, Yanyan
    Castaman, Giancarlo
    HAEMOPHILIA, 2019, 25 (03) : E219 - E222
12345